No disclosed counterparties: XYL, ECL.
| Stage | XYL | % of rev | ECL | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $2.2B | 100.00% | $4.7B | 100.00% | ECL ×2.13 |
| Gross profit | $907M | 41.21% | $2.1B | 44.08% | ECL +2.9pp |
| Operating income | $385M | 17.49% | $811M | 17.26% | XYL +0.2pp |
| Pre-tax income | $365M | 16.58% | $695M | 14.79% | XYL +1.8pp |
| Net income | $288M | 13.08% | $554M | 11.81% | XYL +1.3pp |
| Stage | XYL | ECL | Gap · A − B |
|---|---|---|---|
| Revenue | $2.2B100.00% | $4.7B100.00% | ECL ×2.13 |
| Gross profit | 41.21%$907M | 44.08%$2.1B | ECL +2.9pp |
| Operating income | 17.49%$385M | 17.26%$811M | XYL +0.2pp |
| Pre-tax income | 16.58%$365M | 14.79%$695M | XYL +1.8pp |
| Net income |
| 13.08%$288M |
| 11.81%$554M |
| XYL +1.3pp |